PictorLabs and Hamamatsu Photonics announce strategic partnership to explore virtual staining technology
PictorLabs, an AI-powered virtual staining technology leader, and Hamamatsu Photonics, a renowned whole slide imaging systems provider, have announced a strategic partnership to develop cutting-edge applications for advancing virtual staining in routine laboratory practices. This collaboration aims to explore the growing demand for efficient, scalable digital pathology solutions.
PictorLabs' technology eliminates the need for toxic reagents and reduces turnaround times compared to traditional chemical stain results. Hamamatsu's NanoZoomer series of whole slide scanners is known for its reproducibility and reliability. The partnership seeks to streamline workflows and accelerate the adoption of digital pathology at an enterprise scale.
This collaboration is expected to revolutionize histopathology by combining PictorLabs' AI-powered virtual staining technology with Hamamatsu's state-of-the-art imaging systems, potentially transforming laboratory practices and improving outcomes in research, pharma, and clinical applications.
PictorLabs, leader nella tecnologia di colorazione virtuale alimentata dall'IA, e Hamamatsu Photonics, noto fornitore di sistemi di imaging a diapositiva intera, hanno annunciato una partnership strategica per sviluppare applicazioni all'avanguardia per il progresso della colorazione virtuale nelle pratiche di laboratorio di routine. Questa collaborazione mira a esplorare la crescente domanda di soluzioni di patologia digitale efficienti e scalabili.
La tecnologia di PictorLabs elimina la necessità di reagenti tossici e riduce i tempi di risposta rispetto ai risultati delle colorazioni chimiche tradizionali. La serie di scanner a diapositiva intera NanoZoomer di Hamamatsu è nota per la sua riproducibilità e affidabilità. La partnership si propone di ottimizzare i flussi di lavoro e accelerare l'adozione della patologia digitale su scala aziendale.
Questa collaborazione è destinata a rivoluzionare l'istopatologia combinando la tecnologia di colorazione virtuale alimentata dall'IA di PictorLabs con i sistemi di imaging all'avanguardia di Hamamatsu, trasformando potenzialmente le pratiche di laboratorio e migliorando i risultati nella ricerca, nella farmaceutica e nelle applicazioni cliniche.
PictorLabs, líder en tecnología de tinción virtual impulsada por IA, y Hamamatsu Photonics, un reconocido proveedor de sistemas de imaginología de diapositivas completas, han anunciado una asociación estratégica para desarrollar aplicaciones innovadoras que avancen la tinción virtual en las prácticas de laboratorio rutinarias. Esta colaboración tiene como objetivo explorar la creciente demanda de soluciones de patología digital eficientes y escalables.
La tecnología de PictorLabs elimina la necesidad de reactivos tóxicos y reduce los tiempos de respuesta en comparación con los resultados de tinciones químicas tradicionales. La serie NanoZoomer de Hamamatsu, conocida por su reproducibilidad y fiabilidad, se incluye en esta asociación, que busca optimizar los flujos de trabajo y acelerar la adopción de la patología digital a gran escala.
Se espera que esta colaboración revolucione la histopatología al combinar la tecnología de tinción virtual impulsada por IA de PictorLabs con los sistemas de imagen de última generación de Hamamatsu, transformando potencialmente las prácticas de laboratorio y mejorando los resultados en investigación, farmacéutica y aplicaciones clínicas.
PictorLabs는 AI 기반 가상 염색 기술의 선두주자로, Hamamatsu Photonics는 전체 슬라이드 이미징 시스템의 저명한 제공업체로, 전략적 파트너십을 발표하여 일상 실험실 관행의 가상 염색 발전을 위한 첨단 응용 프로그램을 개발합니다. 이 협력은 효율적이고 확장 가능한 디지털 병리학 솔루션에 대한 증가하는 수요를 조사하는 것을 목표로 하고 있습니다.
PictorLabs의 기술은 독성 시약의 필요성을 없애고 전통적인 화학 염색 결과에 비해 처리 시간을 단축합니다. Hamamatsu의 NanoZoomer 시리즈 전체 슬라이드 스캐너는 재현성과 신뢰성으로 잘 알려져 있습니다. 이 파트너십은 워크플로우를 간소화하고 디지털 병리학의 채택을 가속화하는 것을 목표로 합니다.
이 협력은 PictorLabs의 AI 기반 가상 염색 기술과 Hamamatsu의 최첨단 이미징 시스템을 결합하여 조직병리학을 혁신할 것으로 기대되며, 실험실 관행을 변화시키고 연구, 제약 및 임상 응용에서 결과를 향상시킬 수 있습니다.
PictorLabs, leader dans la technologie de teinture virtuelle propulsée par l'IA, et Hamamatsu Photonics, un fournisseur renommé de systèmes d'imagerie à diapositive entière, ont annoncé un partenariat stratégique pour développer des applications de pointe visant à faire progresser la teinture virtuelle dans les pratiques de laboratoire de routine. Cette collaboration vise à explorer la demande croissante pour des solutions de pathologie numérique efficaces et évolutives.
La technologie de PictorLabs élimine le besoin de réactifs toxiques et réduit les délais de traitement par rapport aux résultats de teinture chimique traditionnels. La série d'appareils NanoZoomer de Hamamatsu, connue pour sa reproductibilité et sa fiabilité, est au cœur de ce partenariat, qui vise à rationaliser les flux de travail et à accélérer l'adoption de la pathologie numérique à grande échelle.
Cette collaboration devrait révolutionner l'histopathologie en combinant la technologie de teinture virtuelle propulsée par l'IA de PictorLabs avec les systèmes d'imagerie de pointe de Hamamatsu, transformant potentiellement les pratiques de laboratoire et améliorant les résultats en recherche, en pharmacie et dans les applications cliniques.
PictorLabs, ein führender Anbieter von KI-gestützter virtueller Färbetechnologie, und Hamamatsu Photonics, ein renommierter Anbieter von Ganzblatt-Imaging-Systemen, haben eine strategische Partnerschaft bekannt gegeben, um fortschrittliche Anwendungen für die Verbesserung der virtuellen Färbung in den routinemäßigen Laborpraktiken zu entwickeln. Ziel dieser Zusammenarbeit ist es, die wachsende Nachfrage nach effizienten, skalierbaren digitalen pathologischen Lösungen zu erkunden.
Die Technologie von PictorLabs beseitigt die Notwendigkeit giftiger Reagenzien und verkürzt die Bearbeitungszeiten im Vergleich zu traditionellen chemischen Färbungen. Die NanoZoomer-Serie von Hamamatsu ist für ihre Reproduzierbarkeit und Zuverlässigkeit bekannt. Die Partnerschaft zielt darauf ab, Arbeitsabläufe zu optimieren und die Akzeptanz der digitalen Pathologie im Unternehmensmaßstab zu beschleunigen.
Diese Zusammenarbeit wird voraussichtlich die Histopathologie revolutionieren, indem sie die KI-gestützte virtuelle Färbetechnologie von PictorLabs mit den hochmodernen Bildgebungssystemen von Hamamatsu kombiniert und potenziell die Laborpraktiken transformiert sowie die Ergebnisse in Forschung, Pharma und klinischen Anwendungen verbessert.
- Strategic partnership between PictorLabs and Hamamatsu Photonics to advance virtual staining technology
- Potential to streamline workflows and accelerate adoption of digital pathology at enterprise scale
- PictorLabs' technology reduces turnaround times and eliminates need for toxic reagents
- Combination of AI-powered virtual staining and state-of-the-art imaging systems may revolutionize histopathology
- None.
Innovations with AI and advanced imaging
PictorLabs, a rapidly growing startup spun off from the UCLA Colleges of Engineering and Medicine, has been at the forefront of the digital transformation of histopathology. By leveraging AI-powered algorithms, PictorLabs eliminates the need for toxic reagents while significantly reducing turnaround times when compared to traditional chemical stain results. With PictorLabs technology and the ability to run multiple stains on a single slide, clinicians and researchers will be able to access digitally stained slides in minutes, enabling faster experiments, less tissue consumption, and better-informed insights.
Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (
The collaboration between PictorLabs and Hamamatsu Photonics aims to explore the growing demand for efficient, scalable digital pathology solutions that can ultimately streamline the workflows and accelerate the adoption of digital pathology at an enterprise scale.
Quotes
"This partnership marks a significant milestone in the digital transformation of pathology," said Yair Rivenson, CEO, CTO & Co-Founder of PictorLabs. "By combining our AI-powered virtual staining technology with Hamamatsu's state-of-the-art imaging systems, we are poised to revolutionize the way laboratories approach histopathology."
"As we look into the future of pathology, we aim to explore areas that not only hold potential but also showcase the innovative spirit of Hamamatsu. We are excited to explore these possibilities with Pictor Labs," said Earl Hergert, President/CEO at Hamamatsu Corporation.
About Hamamatsu Corporation
Hamamatsu Corporation is the North American subsidiary of Hamamatsu Photonics K.K. (
About Pictor Labs
PictorLabs is a software company that is transforming the practice of histopathology with AI-powered virtual staining. Based in
Information furnished by Hamamatsu Corporation is believed to be reliable. However, no responsibility is assumed for possible inaccuracies or omissions. Specifications are subject to change without notice.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pictorlabs-and-hamamatsu-photonics-announce-strategic-partnership-to-explore-virtual-staining-technology-302266959.html
SOURCE Hamamatsu Corporation
FAQ
What is the purpose of the strategic partnership between PictorLabs and Hamamatsu Photonics (HPHTY)?
How does PictorLabs' virtual staining technology benefit laboratories?
What is Hamamatsu Photonics (HPHTY) known for in the digital pathology field?
How might the PictorLabs and Hamamatsu Photonics (HPHTY) partnership impact the histopathology industry?
